| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/04/2001 | WO2001000849A1 Tankyrase2 materials and methods |
| 01/04/2001 | WO2001000828A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | WO2001000822A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 01/04/2001 | WO2001000648A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000612A2 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000566A2 Substituted phenoxyacetic acids |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000245A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000239A1 Combinations of dopamine receptor antagonists with dopamine agonists |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000227A1 Gonadotropin releasing hormone antagonist |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000221A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | WO2001000219A1 Compositions and methods for the treatment of skin disorders |
| 01/04/2001 | WO2001000217A1 Medicinal compositions for preventing or treating diarrhea |
| 01/04/2001 | WO2001000216A1 Novel pharmaceutical combination based on erythromycin and a carboxylic acid having 7 to 13 carbon atoms |
| 01/04/2001 | WO2001000215A1 Compositions for treating or preventing neurodegeneration and cognitive decline |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000213A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000204A1 Method and pharmaceutical composition for parenteral administration of iron |
| 01/04/2001 | WO2001000197A2 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | WO2001000189A2 Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments |
| 01/04/2001 | WO2001000187A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 01/04/2001 | WO2001000184A2 Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments |
| 01/04/2001 | WO2001000183A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 01/04/2001 | WO2001000181A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/04/2001 | WO2001000015A1 Goodpasture's syndrome model mouse |
| 01/04/2001 | WO2000062769A3 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000053236A3 Methods and compositions for targeted drug delivery |
| 01/04/2001 | WO2000038715A3 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | WO2000000161A3 Methods for identification of tef-3 interacting factors |
| 01/04/2001 | CA2727172A1 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 01/04/2001 | CA2385798A1 Substituted phenoxyacetic acids |
| 01/04/2001 | CA2383546A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2380873A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | CA2378563A1 Compositions and methods for the treatment of skin disorders |
| 01/04/2001 | CA2377752A1 Methods and compositions relating to pancreatic islet and .beta.-cell dysfunction |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2377163A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376938A1 Medicinal compositions for preventing or treating diarrhea |
| 01/04/2001 | CA2376935A1 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376892A1 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | CA2376881A1 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2376213A1 Therapeutic agents |
| 01/04/2001 | CA2370687A1 Nucleic acid binding of multi-zinc finger transcription factors |
| 01/04/2001 | CA2370568A1 Tankyrase2 materials and methods |
| 01/04/2001 | CA2370517A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | CA2341974A1 Gonadotropin releasing hormone antagonist |
| 01/03/2001 | EP1065215A1 Homomeric and heteromeric AMPA receptors |
| 01/03/2001 | EP1064967A2 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine |
| 01/03/2001 | EP1064966A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064964A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064948A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064945A1 Therapeutic use of a helium/oxygen mixture, especially for treating asthma |
| 01/03/2001 | EP1064941A1 Use of melatoninergic ligands for obtaining pharmaceutical compositions for the prevention or the treatment of gastrointestinal pathologies |
| 01/03/2001 | EP1064940A1 Antiviral therapy |
| 01/03/2001 | EP1064937A1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/03/2001 | EP1064382A2 Polypeptides homologous to vegf and bmp1 |
| 01/03/2001 | EP1064380A1 EXPRESSION OF THE $i(INSL4) GENE IN HUMAN EMBRYONIC BONE TISSUES AND APPLICATIONS |
| 01/03/2001 | EP1064376A2 GFR$g(a)3 AND ITS USES |
| 01/03/2001 | EP1064364A1 The cytokine family member 2-21 |
| 01/03/2001 | EP1064362A1 Nek1-related protein kinase |
| 01/03/2001 | EP1064303A1 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 01/03/2001 | EP1064301A1 Bacterial yael family members as targets for antimicrobial drug design |
| 01/03/2001 | EP1064295A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS |
| 01/03/2001 | EP1064027A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064023A1 Products in the treatment of cancer |
| 01/03/2001 | EP1064017A1 A method for the prevention of a patient's fibroproliferative vasculopathy |
| 01/03/2001 | EP1064007A1 nrdG |
| 01/03/2001 | EP1064001A2 Methods and compositions for treating and preventing mucositis |
| 01/03/2001 | EP1063998A1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/03/2001 | EP1063997A2 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 01/03/2001 | EP1063995A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 01/03/2001 | EP1063991A1 Statin-matrix metalloproteinase inhibitor combinations |
| 01/03/2001 | EP1063989A1 Prevention and treatment of adhesions |
| 01/03/2001 | EP1063987A1 Dietary control of arachidonic acid metabolism |
| 01/03/2001 | EP1063980A2 Methods for decreasing beta amyloid protein production |
| 01/03/2001 | EP1063978A1 Method of treating neuroma pain |
| 01/03/2001 | EP1063966A1 Methods for regulating skin appearance |
| 01/03/2001 | EP1063888A1 Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors |
| 01/03/2001 | EP0902624B1 Composition and its use as a food supplement or for lowering lipids in serum |
| 01/03/2001 | EP0722312B1 Pharmaceutical composition to enhance tissue healing and regeneration and application kit comprising it |
| 01/03/2001 | CN1278739A Method of delivering genes to antigen presenting cells of the skin |
| 01/03/2001 | CN1278738A Release-sustaining agent for drugs and sustained-release pharmaceutical composition containing same |
| 01/03/2001 | CN1278734A Methods and compositions for treating rheumatoid arthritis |